NSE: MANKIND | BSE: 543904

Expensive Rocket

Download real time

2524.40 -0.70 (-0.03%)

32.19% Gain from 52W Low

93,948 NSE+BSE Volume

NSE 13 Jul, 2026 12:14 PM (IST)

104,256.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Search Inside the pdf :

Mankind Pharma Ltd.

24 Jun 2026

2524.40

-0.03%

Mankind Pharma Initiating Coverage Report

Buy: Mankind Pharma Ltd.

Joindre Capital Services

Rising Chronic Portfolio to Improve Growth Quality: The company is progressively increasing its penetration of specialty chronic therapies namely cardiology and diabetes. The pivot to chronic therapies would further add to stability in revenues, operating margins, and long-term earnings power on account of high repeat nature of chronic segment prescription and greater brand stickiness. BSV Acquisition Strengthens Specialty Business: Purchase of BSV bolstered the specialty business and led to a significant leap in women's...

Mankind Pharma Ltd. has an average target of 2759.33 from 4 brokers.

Mankind Pharma Ltd.

16 Jun 2026

2524.40

-0.03%

MANKIND PHARMA LIMITED

Accumulate: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is a multinational pharmaceutical and healthcare product company, headquartered in Delhi. It manufactures products in therapeutic areas ranging from...

Mankind Pharma Ltd. is trading above all available SMAs

Mankind Pharma Ltd.

21 May 2026

2524.40

-0.03%

BP Equities Q4FY26 Result Update Mankind Pharma Ltd.

Results Update: Mankind Pharma Ltd.

BP Wealth

...

Number of FII/FPI investors decreased from 575 to 568 in Mar 2026 qtr

Mankind Pharma Ltd.

29 Apr 2026

2524.40

-0.03%

Domestic formulation on revival mode; BSV scaling up

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind’s domestic formulation (DF) business is witnessing a healthy revival, with Mar’26 growth at 11.5% YoY vs. IPM growth at 10.6% (1.1pp outperformance).

Mankind Pharma Ltd. has an average target of 2759.33 from 4 brokers.

Mankind Pharma Ltd.

04 Feb 2026

2524.40

-0.03%

BP Equities Q3FY26 Result Update Mankind Pharma Ltd

Results Update: Mankind Pharma Ltd.

BP Wealth

...

Joindre Capital Services released a Buy report for Mankind Pharma Ltd. with a price target of 2978.0 on 24 Jun, 2026.

Mankind Pharma Ltd.

16 Dec 2025

2524.40

-0.03%

BP Equities Mankind Pharma Initiating Coverage BUY Target 2,652

Buy: Mankind Pharma Ltd.

BP Wealth

Joindre Capital Services released a Buy report for Mankind Pharma Ltd. with a price target of 2978.0 on 24 Jun, 2026.

Mankind Pharma Ltd.

26 Nov 2025

2524.40

-0.03%

MANKIND PHARMA LIMITED

Buy: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in New Delhi. The company has products in therapeutic areas...

Mankind Pharma Ltd. is trading above all available SMAs

Mankind Pharma Ltd.

07 Nov 2025

2524.40

-0.03%

2Q in line; transition phase underway

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered a largely in-line financial performance for 2QFY26. EBITDA was slightly lower than estimates due to higher employee costs.

Mankind Pharma Ltd. has an average target of 2759.33 from 4 brokers.

Mankind Pharma Ltd.

01 Aug 2025

2524.40

-0.03%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. is trading above all available SMAs

Mankind Pharma Ltd.

22 May 2025

2524.40

-0.03%

Higher marketing/promotional costs drive a miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line revenue in 4QFY25; however, EBITDA/PAT came in 14%/12% below our estimates. Higher-than-expected spending on marketing and promotional activities affected the company’s 4Q performance.